Assertio Announces First-Ever Real-World Study of Patient Experience with SYMPAZAN (clobazam) Oral Film for Lennox-Gastaut Syndrome (CIV)

A groundbreaking real-world evaluation of SYMPAZAN (clobazam) oral film reveals how this once-tablet-based therapy is being integrated into daily care for Lennox-Gastaut Syndrome (LGS) and other epilepsy conditions. The study, presented in a poster session at a major neurology conference, sheds light on patient demographics, concomitant medications, and comorbidities in real-world settings. It emphasizes the role of an orally dissolving film formulation for patients who face swallowing difficulties or who require convenient administration during ongoing treatment plans. The findings aim to inform clinicians about how clobazam oral film is utilized in practice, how it complements existing regimens, and how it may influence treatment decisions for pediatric and adult patients across the epilepsy spectrum.

Real-World Study: Scope, Design, and Demographics

The real-world study sought to illuminate how clobazam oral film is used in everyday clinical practice, focusing on patient demographics, concomitant antiseizure medications, and coexisting health conditions in individuals with epilepsy or Lennox-Gastaut Syndrome who had prior exposure to clobazam oral soluble film. The study identified a total of 181 patients with epilepsy and a focused subset of 29 patients diagnosed with LGS. The analysis draws on data from electronic health records obtained during routine clinical care across a ten-year window, spanning 2015 through 2024, with a retrospective, new-user cohort study design. This methodological choice enables researchers to capture initial, real-world usage patterns rather than data derived solely from controlled clinical trials. The patient population included individuals treated for epilepsy or LGS and who had been documented as taking clobazam oral soluble film, thus enabling an examination of demographics, antiseizure medication usage, and coexisting health conditions as they manifested in real-world settings.

Across the broader epilepsy cohort, the study observed a spectrum of demographic characteristics, varying concomitant therapies, and a range of comorbidities, reflecting the heterogeneity of real-world epilepsy care. Within the LGS subgroup, age appeared notably younger on average when compared to the broader epilepsy cohort. Specifically, the LGS group had a mean age of approximately 13.6 years, whereas the epilepsy group averaged around 21.1 years. This age difference underscores the pediatric predominance of LGS and highlights the practical implications of treatment choices in younger patients who may face unique challenges in seizure management and tolerability. The LGS patients in the study also demonstrated a higher tendency to transition from clobazam tablets or oral suspensions to the oral film formulation, suggesting potential preferences or clinical considerations related to swallowing ability, dosing convenience, and adherence. Additionally, cannabidiol use was more prevalent among the LGS subset, pointing to a tendency for clinicians to integrate multiple pharmacologic strategies in this more complex subgroup of patients.

The real-world nature of the dataset lends practical value to clinicians by outlining how patients with epilepsy or LGS actually utilize clobazam oral film in varied therapeutic contexts. The study provides a window into everyday clinical decisions, including when to switch formulations, how to balance polytherapy with clobazam, and how coexisting conditions may influence the choice and sequencing of medications. Overall, the data emphasize the importance of recognizing a diverse patient population and the ways in which an oral film formulation can be integrated into individualized treatment plans for LGS and broader epilepsy management. The study’s conclusions point to meaningful real-world insights that can help clinicians tailor regimens to patient needs, improve tolerability, and address practical barriers to achieving optimal seizure control in daily practice.

Patient Demographics and Treatment Trajectories

In the real-world cohort, clinicians observed a diverse array of patient backgrounds, with demographic and clinical characteristics varying widely across individuals with epilepsy or LGS receiving clobazam oral film. Among the LGS patients, the average age was substantially younger than among those with epilepsy alone, illustrating the pediatric focus of LGS management and the potential implications for long-term treatment planning. The study noted that a higher proportion of LGS patients had transitioned from traditional clobazam tablet formulations or suspensions to the oral film form, indicating practical preferences or clinical judgments about administration ease, swallow safety, and consistent dosing. In addition, cannabidiol usage was disproportionately represented among the LGS group, hinting at a broader therapeutic strategy in this particular subgroup that combines anticonvulsant pharmacology with treatment approaches addressing comorbid symptoms such as behavioral or cognitive challenges.

From a care delivery standpoint, the real-world data illuminate how clinicians leverage the convenience and tolerability profile of an oral film to support ongoing seizure management. The observed demographic spread and treatment transitions reflect deliberate, patient-centered decision-making in the context of LGS and broader epileptic conditions. This granular, practice-based information can be instrumental for clinicians seeking to align pharmacotherapy with individual patient preferences, comorbidity profiles, and sedation risk considerations that often accompany polytherapy in epilepsy care.

Implications for Practice and Patient Experience

The real-world evidence underscores the potential for an oral film format to facilitate treatment initiation and continuity for patients who may struggle with tablet swallowing or liquid formulations. The findings suggest that the oral film technology can be particularly advantageous for younger patients with LGS, where swallowing difficulties and variability in medication administration can impede adherence and consistent seizure control. Clinicians may view the oral film as a practical option that supports stable dosing, easier administration during school or activities, and improved overall adherence in a real-world setting. The study’s data also highlight how clinicians incorporate clobazam oral film into complex regimens, particularly for those requiring adjunctive therapy in LGS and those who may be integrating cannabidiol as part of a broader treatment strategy. Taken together, these insights can inform clinical guidelines, patient education, and caregiver support, helping to optimize therapeutic outcomes for individuals living with epilepsy and LGS in everyday life.

Clinical Insights: How SYMPAZAN Oral Film Is Used in Daily Practice

SYMPAZAN, the first and only FDA-approved oral film formulation of clobazam, is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients two years of age and older. The oral film is flavored with a berry profile and comes in 5 mg, 10 mg, and 20 mg dosages, matching the dosing options available with other clobazam formulations. This formulation is designed to offer a convenient and reliable administration route for patients who benefit from a non-pill delivery system, while maintaining the therapeutic effects of clobazam in reducing seizure frequency and severity in LGS.

The real-world study provides context for how clinicians apply SYMPAZAN in practice beyond controlled trial environments. Clinicians reported that patients with LGS, particularly younger children, may have improved adherence and tolerability with the oral film compared to traditional solid or liquid formulations. The ease of administration is especially relevant for patients who require consistent daily dosing as part of an ongoing treatment plan, and for caregivers seeking predictable medication delivery during daily routines. In practice, clobazam oral film is being used as an adjunctive therapy, integrated with existing antiseizure medications to maintain seizure control while addressing individual patient needs, including swallowing difficulties, appetite fluctuations, or tolerability concerns.

Swallowing Difficulties and Administration Convenience

A central practical finding from the real-world data is the role of the oral film’s tablet-dissolution properties in addressing swallowing difficulties. For patients with LGS and for those who struggle with tablets, the film provides a reliable alternative that can reduce administration-related barriers to adherence. Clinicians observed that switching from tablets or suspensions to the oral film could streamline dosing, minimize caregiver burden, and potentially improve consistency in daily intake. The daily management of LGS often involves complex regimens, and the oral film’s user-friendly format may support smoother integration into daily activities, school schedules, and family routines. This practical advantage aligns with broader goals in epilepsy care to improve patient quality of life while preserving optimal seizure control.

Cannabidiol Co-Administration and Polytherapy Considerations

The real-world study highlighted higher cannabidiol use within the LGS subgroup, suggesting that clinicians commonly employ a multi-agent approach to address the multifaceted challenges of LGS. In practice, clobazam oral film is used alongside other therapies, including cannabidiol, as part of comprehensive treatment plans tailored to individual patient profiles. Healthcare providers must consider potential drug–drug interactions, overlapping adverse effects, and the cumulative burden of polytherapy. The real-world data, by detailing co-medications and comorbidities, provide a practical framework for clinicians to monitor interactions, adjust dosages, and maintain safety while striving for the best possible seizure outcomes. This nuanced understanding of how SYMPAZAN fits into polytherapy regimens helps clinicians balance efficacy with tolerability in diverse patient populations.

Real-World Outcomes: Demographics, Medications, and Comorbidities

In broad terms, the study’s real-world outcomes reflect a heterogeneous epilepsy population in which SYMPAZAN oral film is used across a spectrum of ages, clinical histories, and treatment regimens. The LGS subset, characterized by younger age and a tendency to switch from older clobazam formulations, represents a meaningful subgroup in which the oral film could enhance administration convenience and adherence. The observed patterns in concomitant antiseizure medications and the prevalence of comorbidities offer clinicians practical insights for anticipating potential safety considerations and for planning comprehensive care that accounts for the full clinical picture of each patient. The real-world evidence thus contributes to a more nuanced understanding of how clobazam oral film functions within the broader pharmacologic landscape of epilepsy management.

Implications for Clinical Decision-Making

From a clinical decision-making perspective, the study’s findings support the rationale for considering an oral film formulation for patients with LGS who face swallowing challenges or require a straightforward dosing strategy. The real-world data highlight the potential benefits of initiating clobazam treatment with an oral film in appropriate patients and underscore the importance of monitoring for efficacy, tolerability, and adherence over time. Clinicians may use these insights to guide conversations with patients and families about administration preferences, potential formulation switches, and the role of adjunctive therapies in achieving durable seizure control. The practical knowledge gained from real-world settings complements randomized trial data, offering a comprehensive view of how SYMPAZAN can be integrated into individualized epilepsy care plans.

Safety, Tolerability, and Adverse-Event Profile in Real-World Use

SYMPAZAN is associated with a range of safety considerations that clinicians weigh during therapy. The product labeling emphasizes risks related to concomitant use with opioids, as well as concerns about abuse, misuse, dependence, withdrawal, and potential respiratory depression when benzodiazepines are used with other central nervous system depressants. In the context of real-world use, these safety considerations remain central to patient selection, dose optimization, and ongoing monitoring. Clinicians must assess each patient’s risk for abuse, misuse, and addiction, and they should pursue the lowest effective dose while avoiding or minimizing exposure to other CNS depressants or substances associated with abuse. If a patient experiences signs of withdrawal or became dependent, a careful taper strategy should be implemented under medical supervision to minimize life-threatening withdrawal reactions.

The safety profile also includes warnings about dermatologic reactions, such as serious skin eruptions that could indicate conditions like Stevens-Johnson syndrome or toxic epidermal necrolysis. If a rash appears, clinicians are advised to discontinue therapy unless the rash is clearly unrelated to the drug. The potential for drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported among antiepileptic drugs, including clobazam, and clinicians must evaluate signs such as fever, rash, lymphadenopathy, and facial swelling promptly, discontinuing SYMPAZAN if an alternative etiology cannot be established. The potential for suicidal ideation and behavior is another important safety consideration for antiepileptic medications, requiring ongoing monitoring of mood and behavior changes in patients treated for any indication.

The labeling also addresses pregnancy and lactation, highlighting that benzodiazepines cross the placenta and can cause neonatal respiratory depression, hypotonia, sedation, or withdrawal symptoms in newborns. Neonates exposed to SYMPAZAN during pregnancy or labor should be monitored for sedation and withdrawal signs, and breastfeeding considerations must balance maternal need with potential infant effects such as sedation or poor feeding. In the event of overdosage, benzodiazepine-related central nervous system depression can range from drowsiness to coma, and management typically involves supportive care and airway protection. While specific rescue agents like flumazenil exist, their use is nuanced and potentially risks-associated, including withdrawal seizures, particularly in patients with epilepsy. Clinicians should follow established guidelines for overdose management and consult specialists when needed.

In addition to these safety considerations, the warning framework emphasizes avoiding abrupt discontinuation or rapid dose reductions to prevent withdrawal reactions. Gradual tapering is recommended to minimize risks, and clinicians should be mindful of interactions with opioids and other CNS depressants that could potentiate sedation and respiratory depression. Adverse reactions that occur in real-world settings, such as constipation, somnolence, fever, lethargy, and drooling, are highlighted as more frequent than placebo in clinical experience. Drug interactions are also important in real-world use; benzodiazepines with opioids increase the risk of respiratory depression, while combinations with CNS depressants or alcohol may magnify sedative effects. The safety profile underscores the need for careful patient selection, dose optimization, counseling about risks, and proactive monitoring to maintain a favorable benefit-risk balance in epilepsy management.

Drug Interactions and Special Considerations

The real-world data underscore several important drug interaction considerations when SYMPAZAN is co-administered with other medications. Notably, opioids can amplify respiratory depression when combined with benzodiazepines, necessitating careful dose management and vigilant monitoring. Co-administration with CNS depressants or alcohol may enhance sedative effects, so clinicians should educate patients and caregivers about the risks and avoid concurrent use where possible. Hormonal contraceptives that are metabolized by CYP3A4 may have reduced effectiveness when used with SYMPAZAN, prompting recommendations for additional non-hormonal contraception methods. SYMPAZAN inhibits the CYP2D6 enzyme, which may require dose adjustments for drugs metabolized by CYP2D6 when used together. The potential interactions with strong and moderate inhibitors of CYP2C19 may necessitate dosage adjustments of SYMPAZAN in certain contexts. Coadministration with cannabidiol can increase the risk of SYMPAZAN-related adverse reactions, and may require dose reductions of either cannabidiol or SYMPAZAN in some cases.

Pregnancy, Lactation, and Neonatal Considerations

Pregnancy discussions for patients on SYMPAZAN should acknowledge the broader data on benzodiazepines, which do not show a definitive link to major birth defects but do indicate possible neonatal sedation or withdrawal symptoms. Neonates exposed to benzodiazepines late in pregnancy should be monitored for sedation, respiratory depression, hypotonia, and feeding challenges, and appropriate clinical management should be implemented. For lactation, benzodiazepines can be excreted in human milk, and the infant should be observed for sedation, poor feeding, and weight gain issues. In deciding on SYMPAZAN during pregnancy or breastfeeding, clinicians must weigh maternal benefits against potential infant risks and discuss these considerations with patients.

Implications for Lennox-Gastaut Syndrome Management and Treatment Planning

Lennox-Gastaut Syndrome is a severe epilepsy disorder that predominantly manifests in childhood and is characterized by multiple seizure types, cognitive and behavioral comorbidities, and a challenging treatment landscape. The syndrome affects a subset of the population in which real-world data for antiseizure medications like clobazam are especially valuable for understanding how therapies perform outside controlled environments. The real-world study highlights that LGS is a population with unique needs, including the importance of administration convenience, tolerability, and the potential for combination therapies that may address broader symptom complexity beyond seizures alone. The availability of an oral film formulation of clobazam offers clinicians another option to tailor regimens to patient preferences and practical realities, potentially improving adherence and, by extension, seizure control in daily life.

From a clinical perspective, these real-world insights support the rationale for considering oral film formulations in patients with LGS who require adjunctive therapy and who present with swallowing difficulties or adherence barriers. By providing a delivery system that aligns with patient and caregiver preferences, the oral film form can complement other antiseizure medications to achieve a more stable therapeutic regimen. Clinicians can use this information to discuss treatment options with families, set realistic expectations about efficacy and tolerability, and monitor responses across a range of real-world scenarios. The findings also emphasize the importance of integrating real-world evidence into clinical decision-making, enabling more informed choices about drug selection, formulation, and dosing in LGS and broader epilepsy care.

Practical Guidance for Clinicians and Caregivers

For clinicians, the study reinforces the value of considering patient-specific factors such as age, swallowing ability, and concurrent therapies when selecting a clobazam formulation. The preference for oral film in patients with swallow difficulties suggests potential improvements in adherence and consistency of dosing, which are critical for maintaining seizure control in LGS. Caregivers play a central role in daily administration, and the oral film’s ease of use can reduce caregiver burden, particularly for younger patients who rely on routine daily doses. Real-world data indicating higher cannabidiol use in LGS patients point to the need for coordinated care among neurologists, pediatric specialists, and caregivers to optimize treatment plans, monitor interactions, and address cognitive and behavioral comorbidities alongside seizure management.

Limitations and Context for Real-World Data

As with any real-world evidence, the study’s retrospective design and reliance on electronic health records introduce limitations that clinicians should consider. The data reflect care patterns at a specific set of institutions over a defined period and may not capture all variations in practice across different regions or healthcare systems. Nevertheless, the findings offer a meaningful snapshot of how SYMPAZAN oral film is applied in ordinary clinical settings and how it interacts with other therapies in diverse patient populations. The real-world context complements randomized trial data, helping to bridge the gap between controlled efficacy and practical effectiveness. Clinicians should interpret these results in light of study design, potential selection bias, and the generalizability of the patient cohort to their own practice.

About SYMPAZAN, Clobazam Oral Film, and Assertio

SYMPAZAN represents a pioneering advancement in clobazam therapy, offering the first and only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients aged two years and older. The berry-flavored oral film is designed to provide a convenient, swallow-friendly option that aligns with the needs of both pediatric and adult patients managing LGS and other epilepsy conditions. Available in multiple dosages, the formulation supports flexible dosing to accommodate individual patient requirements and treatment responses, while maintaining the therapeutic intent of clobazam.

Assertio, the company behind SYMPAZAN, positions itself as a pharmaceutical organization focused on delivering differentiated products that address patient needs across oncology, neurology, and pain management. The company emphasizes a commitment to comprehensive commercial capabilities and patient-centered care, aiming to support patients with innovative therapies that improve quality of life and treatment outcomes. The broader strategic focus includes expanding market reach and optimizing the healthcare experience for patients requiring neurologic and other targeted therapies. While the real-world data highlight the potential benefits of oral film formulations, clinicians should rely on a combination of clinical judgment, patient preferences, and robust safety monitoring when integrating new formulations into treatment plans.

About Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome is a severe and relatively rare epilepsy disorder that commonly emerges in early childhood, typically diagnosed between ages three and five, though delayed diagnoses occur in some cases. Individuals with LGS often experience multiple seizure types and may face cognitive and behavioral challenges alongside epilepsy. The management of LGS is complicated by treatment-resistant seizures and the need for individualized, evolving approaches to address progressive symptoms throughout a patient’s life. The real-world evidence discussed here contributes to a deeper understanding of how treatment options like clobazam oral film may fit into comprehensive care strategies for LGS, with attention to safety, tolerability, and practical administration considerations.

Indications and Usage: What SYMPAZAN Is Approved For

SYMPAZAN is indicated as an adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome in patients two years of age and older. The formulation’s approval reflects its intended role within a broader therapeutic framework for LGS, where flexible dosing and patient-friendly administration can complement other antiseizure medications to achieve improved seizure control and quality of life. This positioning underscores the importance of formulation selection as a critical component of individualized care in pediatric and adult patients living with LGS and related epilepsies.

Safety Information: Key Considerations for Clinicians

The safety information emphasizes important considerations for prescription and monitoring. Clinicians should be vigilant about the potential risks associated with concomitant opioid use, as well as risks of abuse, misuse, and addiction with benzodiazepines, all of which can lead to serious adverse outcomes including respiratory depression and, in severe cases, death. Gradual tapering is advised when discontinuing SYMPAZAN to minimize withdrawal risks, and careful attention should be paid to signs of withdrawal and dependence. The risk of sedation and somnolence, particularly when SYMPAZAN is used with other CNS depressants or alcohol, warrants patient and caregiver education and ongoing monitoring.

Serious dermatologic reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, though rare, require discontinuation of SYMPAZAN at the first sign of rash unless it is clearly not drug-related. DRESS (drug reaction with eosinophilia and systemic symptoms) presents with systemic signs and requires immediate evaluation, with SYMPAZAN discontinued if no alternative cause is identified. The potential for suicidal thoughts or behavior necessitates monitoring for mood changes in all patients treated with antiepileptic drugs, including SYMPAZAN. Neonatal sedation and withdrawal symptoms are possible with exposure during late pregnancy, and infants exposed to benzodiazepines via breastfeeding should be monitored for sedation and feeding issues.

Pregnant or nursing women should engage in thorough risk–benefit discussions, and clinicians should consider enrolling patients in pregnancy registries where appropriate. Overdosage requires supportive measures and careful management, and clinicians should consult toxicology resources for guidance. Given these safety considerations, clinicians must balance seizure control with safety, tailoring therapy to each patient’s risk profile and monitoring needs.

Practical Notes on Administration and Monitoring

To optimize outcomes with SYMPAZAN, clinicians should provide clear patient and caregiver education about proper administration, potential side effects, and signs of adverse reactions. Regular follow-up visits should assess seizure control, tolerability, adherence, and interactions with concomitant medications. In the context of real-world use, ongoing monitoring is essential to ensure that the benefits of clobazam oral film outweigh the risks for each patient, particularly in pediatric populations where growth, development, and comorbidity management intersect with antiepileptic therapy.

The ANA2025 Poster and Real-World Evidence Landscape

The real-world evidence presented in this study aligns with a broader trend toward understanding how epilepsy treatments perform outside clinical trials. Presentations at major neurological meetings, such as the annual conference of the American Neurological Association, provide a platform for researchers and clinicians to share real-world experiences, discuss treatment patterns, and highlight practical implications for patient care. This poster contributes to the growing body of real-world data on clobazam, oral film formulations, and their role in managing Lennox-Gastaut Syndrome and other epilepsy conditions. The findings offer clinicians tangible insights into how real-world practice shapes patient outcomes and how novel formulations can influence daily treatment regimens across diverse patient populations. By documenting actual usage patterns, including formulation switches and concomitant therapies, the presentation underscores the importance of integrating real-world evidence into clinical decision-making as part of a comprehensive approach to epilepsy care.

In the context of ANA2025 and similar meetings, researchers emphasize the value of real-world data in complementing randomized controlled trials. Such data help inform guidelines, inform patient counseling, and support healthcare systems in designing effective, patient-centered epilepsy care pathways. The study’s focus on real-world demographics, medication usage, and comorbidities adds a practical dimension to our understanding of clobazam’s role in daily practice and contributes to ongoing discussions about optimizing therapy for LGS and other seizure disorders.

Additional Context for Healthcare Professionals

Healthcare professionals may use the insights from this real-world study to guide discussions with patients and families about the advantages and limitations of switching to an oral film formulation. The data on younger LGS patients and higher cannabidiol use illuminate common clinical trajectories and decision-making patterns, emphasizing the need for coordinated care and careful monitoring of potential drug interactions. As clinicians accumulate more real-world experience with SYMPAZAN, they can refine patient selection criteria, dosing strategies, and monitoring protocols to maximize therapeutic benefits while minimizing safety concerns.

About Assertio and SYMPAZAN in Clinical Practice

Assertio is a pharmaceutical company focused on delivering differentiated products designed to address patient needs across oncology, neurology, and pain management. The company emphasizes a patient-centered approach, aiming to support individuals facing challenging conditions with therapies that balance efficacy, tolerability, and ease of use. In the realm of neurology, SYMPAZAN stands as a prominent example of how formulation innovation—specifically, an oral film delivery system for clobazam—can translate into real-world benefits for patients with Lennox-Gastaut Syndrome and related epilepsies. While the real-world study offers valuable practical insights, clinicians should combine these findings with comprehensive clinical assessments and guideline-based practices to optimize care for people living with epilepsy.

Summary of SYMPAZAN’s Role in Modern Epilepsy Care

SYMPAZAN’s introduction as an oral film formulation of clobazam adds a practical dimension to epilepsy management by offering a swallow-friendly, flexible dosing option that can be particularly advantageous for pediatric patients and others with swallowing challenges. The real-world study’s findings about demographic patterns, formulation switches, and cannabidiol co-use reinforce the idea that oral film therapy can be a meaningful component of comprehensive, individualized treatment plans. Clinicians, caregivers, and patients may benefit from understanding how this formulation behaves in everyday practice, which can help inform decisions about initiation, continuation, or transition to oral film therapy within established treatment regimens.

Conclusion and Forward Look

The introduction of SYMPAZAN as an oral film formulation of clobazam marks a significant development in the management of Lennox-Gastaut Syndrome and broader epilepsy care. The real-world study provides valuable perspectives on how this therapy is actually used in daily clinical practice, including patient demographics, treatment transitions, and the interplay with other antiseizure medications. By highlighting practical considerations such as swallowing difficulties, administration convenience, and polytherapy dynamics, the study offers actionable insights for clinicians aiming to optimize seizure control while maintaining tolerability and adherence. As real-world evidence continues to accumulate, healthcare professionals can refine treatment strategies, tailor regimens to individual patient needs, and enhance the overall care experience for people living with epilepsy and LGS.

Conclusion

In summary, the real-world findings presented for SYMPAZAN (clobazam) oral film illuminate how this adjunctive therapy is being incorporated into everyday clinical practice for Lennox-Gastaut Syndrome and broader epilepsy management. The data reveal meaningful trends in patient demographics, formulation transitions, and co-medication patterns that have direct implications for clinical decision-making. The oral film’s swallow-friendly design addresses a practical barrier to adherence for patients with swallowing difficulties, while the broader safety profile—encompassing serious adverse event considerations, drug interactions, and withdrawal risks—remains central to patient safety. The study’s emphasis on cannabidiol use within the LGS subgroup further underscores the value of coordinated, multi-agent strategies in complex epilepsy care. For clinicians, caregivers, and patients, these insights can guide informed discussions about treatment options, dosing strategies, and monitoring plans to optimize seizure control and quality of life. As more real-world evidence emerges, the role of SYMPAZAN oral film in personalized epilepsy care will become increasingly nuanced, with ongoing opportunities to improve outcomes for individuals affected by Lennox-Gastaut Syndrome and related seizures.